探索最全面的数据库
1 000 000
债券
100 000
股票
175 910
ETF & Funds
8万
指数
以最有效的方式跟踪您的投资组合
|
Ingenia Therapeutics Inc. (Reg. S) is a U.S.-headquartered, clinical-stage biotechnology company that made history in August 2026 by completing a milestone initial public offering (IPO) of Korea Depositary Receipts (KDRs) on the KOSDAQ market of the Korea Exchange (KRX), marking the first listing of a U.S.-based company on the exchange in over five years
|